The Europe Molecular Diagnostics Market was appreciated at US$ 1750.0 million in the year 2015 and is estimated to reach USD 4.0 billion by 2024. It is anticipated to develop at a substantial CAGR for the duration of the prediction. Europe is a technologically advanced region. Categorized by a huge number of elderly inhabitants, the area has observed a steady growth due to prevalence of long-lasting sicknesses, for instance non-infectious sicknesses, diabetes, and cardiovascular sicknesses.
The Europe molecular diagnostics industry on the source of Type of Application Pharmacogenomics, Neurological Disease, Microbiology, Cardiovascular Disease, Infectious Diseases. The subdivision of Infectious Diseases held the biggest stake of the market, due to the greater occurrence of HIV. It generated the highest income during the year 2015. Furthermore, the progress of new-fangled diagnostics examinations in the range of infectious diseases is emphasizing the development of this market.
The Europe molecular diagnostics market on the source of Type of Technology could span Transcription-mediated Amplification, Mass Spectrometry, Isothermal Nucleic Acid Amplification Technology [INAAT], PCR, [Multiplex PCR], Sequencing, Chips & Microarrays, and In Situ Hybridization. The subdivision of PCR detained the biggest stake of the market nearby the year 2015. It could be credited mostly to the growing use of molecular diagnostics in the arena of pharmacogenomics and the increasing practice of multiplex PCR skills.
The Europe molecular diagnostics industry on the source of Type of Test Location could span Central Laboratories, Point of Care, Self-Test. The subdivision of Point of Care [PoC] is expected to develop at a profitable CAGR above the prediction period. The increasing demand for speedy analysis together with the readiness of freshly developed skill of Point of Care to observe the reactions of medicine, in patients through cardiac sicknesses, will subsidize in the direction of the progress of this subdivision.
The Europe molecular diagnostics market on the source of Type of Product could span Reagents, Instruments, and additional products. The additional products comprise software programs and the services. These are supportive in the administration of the instrumentation procedure. The division was ruled by the subdivision of reagents by means of above 50.0% stake during the year 2015. Reagents comprise SDS, salts, heparin or dextran sulphate, and form amide. These are usually utilized in execution of in-situ hybridization examination.
The subdivision of reagents is likewise projected to boost at a dual digit CAGR above the prediction period. Increasing practice of methods including fluorescence in situ hybridization is contributing to the additional development of this subdivision. The Europe molecular diagnostics market on the source of Area with respect to Trades in terms of intake, Profits, Market stake and Development percentage in these areas, for the duration of the prediction could span Italy, Spain, Germany, France, and the U.K.
By the source of geography, Germany was the biggest market in Europe during the year 2015. It was responsible for a market stake of more than 20.0% of the general market for molecular diagnostics. Growing technical improvements and the base of ageing residents in the arena of molecular diagnostics are the most important factors for the lucrative progress of the market.
Similarly, the UK offers a developing market, in this arena, by means of a well-paid development above the forecast period of prediction. Reasons backing speedy progress of the market consist of existence of a strong substructure of healthcare, gushing per head earnings, and the growing stages of alertness between people for the timely identification of deadly sicknesses, which includes HIV, and Cancer.
The statement revises Trades in terms of intake of Europe Molecular Diagnostics in the market; particularly in Italy, Spain, Germany, France, and the U.K. It concentrates on the topmost companies operating in these regions. Some of the important companies operating in the field are Thermo Fisher Scientific, Inc., Eppendorf AG, QIAGEN N.V, Bio-Rad Laboratories, Inc., Becton Dickinson and Company, Agilent Technologies, Inc., PerkinElmer, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Tecan Group Ltd., Illumina, Inc., Cepheid Inc., Abbott Laboratories, Hologic Inc., Myriad Genetics, Novartis A G, and Gen-probe. Additional notable companies operating in the field are-bioMérieux SA, Dako, Johnson and Johnson, Bayer AG, Alere, Inc., and Siemens Healthcare GmbH.
Europe Molecular Diagnostics Product Outlook (Market Revenue in USD Million, 2013 - 2024)
Europe Molecular Diagnostics Test Location Outlook (Market Revenue in USD Million, 2013 - 2024)
• Point of care
• Self-testing or OTC
• Central laboratories
Europe Molecular Diagnostics Technology Outlook (Market Revenue in USD Million, 2013 - 2024)
• In-situ hybridization
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Chips and microarrays
• Mass spectrometry
• Transcription-mediated amplification
Europe Molecular Diagnostics PCR, by segments Outlook (Market Revenue in USD Million, 2013 - 2024)
• Multiplex PCR
Europe Molecular Diagnostics Application Outlook (Market Revenue in USD Million, 2013 - 2024)
• Infectious diseases
• Genetic testing
• Neurological diseases
• Cardiovascular diseases
Europe Molecular Diagnostics Oncology, By Application Outlook (Market Revenue in USD Million, 2013 - 2024)
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Kidney Cancer
• Liver Cancer
• Blood Cancer
• Lung Cancer
Europe Molecular Diagnostics Infectious Disease, By Application Outlook (Market Revenue in USD Million, 2013 - 2024)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• Clostridium difficile
• Vancomycin-resistant enterococci
• Carbapenem-resistant bacteria testing
• Respiratory syncytial virus (RSV)
• Tuberculosis and drug-resistant TB
• Gastro-intestinal panel testing
• Hepatitis C
• Hepatitis B
Europe Molecular Diagnostics Genetic Testing, By Application Outlook (Market Revenue in USD Million, 2013 - 2024)
• Newborn screening
• Predictive and presymptomatic testing
Europe Molecular Diagnostics Country Outlook (Market Revenue in USD Million, 2013 - 2024)
Research Support Specialist, USA